A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.
Goodkin, D E
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. [electronic resource] - Neurology Apr 2000 - 1414-20 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0028-3878
10.1212/wnl.54.7.1414 doi
Adult
Autoantibodies--blood
Brain--pathology
Dose-Response Relationship, Immunologic
Double-Blind Method
Female
HLA Antigens--immunology
HLA-DR2 Antigen--immunology
Humans
Immunotherapy
Interferon-gamma--metabolism
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive--blood
Myelin Basic Protein--adverse effects
Myelin Proteins
Myelin-Associated Glycoprotein--immunology
Myelin-Oligodendrocyte Glycoprotein
Peptide Fragments--adverse effects
T-Lymphocytes--immunology
Treatment Outcome
Vaccines, Conjugate--adverse effects
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis. [electronic resource] - Neurology Apr 2000 - 1414-20 p. digital
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0028-3878
10.1212/wnl.54.7.1414 doi
Adult
Autoantibodies--blood
Brain--pathology
Dose-Response Relationship, Immunologic
Double-Blind Method
Female
HLA Antigens--immunology
HLA-DR2 Antigen--immunology
Humans
Immunotherapy
Interferon-gamma--metabolism
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive--blood
Myelin Basic Protein--adverse effects
Myelin Proteins
Myelin-Associated Glycoprotein--immunology
Myelin-Oligodendrocyte Glycoprotein
Peptide Fragments--adverse effects
T-Lymphocytes--immunology
Treatment Outcome
Vaccines, Conjugate--adverse effects